Cargando…

In Vivo Assessment of SMT19969 in a Hamster Model of Clostridium difficile Infection

SMT19969 [2,2′-bis(4-pyridyl)3H,3′-H 5,5-bibenzimidazole] is a novel narrow-spectrum nonabsorbable antibiotic currently in development for the treatment of Clostridium difficile infection. The comparative activities of SMT19969 and vancomycin against nonepidemic and epidemic strains of C. difficile...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weiss, William, Pulse, Mark, Vickers, Richard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2014
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4187990/ https://www.ncbi.nlm.nih.gov/pubmed/25022586 http://dx.doi.org/10.1128/AAC.02903-14

Ejemplares similares

SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI
por: Sattar, Abdul, et al.
Publicado: (2015)

In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile
por: Corbett, D., et al.
Publicado: (2015)

Susceptibility of Clostridium difficile Isolates of Varying Antimicrobial Resistance Phenotypes to SMT19969 and 11 Comparators
por: Freeman, Jane, et al.
Publicado: (2015)

Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection
por: Bassères, Eugénie, et al.
Publicado: (2016)

SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model
por: Baines, S. D., et al.
Publicado: (2015)

A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections
por: Vickers, Richard, et al.
Publicado: (2015)

Comparative In Vitro Activities of SMT19969, a New Antimicrobial Agent, against 162 Strains from 35 Less Frequently Recovered Intestinal Clostridium Species: Implications for Clostridium difficile Recurrence
por: Goldstein, Ellie J. C., et al.
Publicado: (2014)

Comparative In Vitro Activities of SMT19969, a New Antimicrobial Agent, against Clostridium difficile and 350 Gram-Positive and Gram-Negative Aerobic and Anaerobic Intestinal Flora Isolates
por: Goldstein, Ellie J. C., et al.
Publicado: (2013)

Bacteriophage Combinations Significantly Reduce Clostridium difficile Growth In Vitro and Proliferation In Vivo
por: Nale, Janet Y., et al.
Publicado: (2016)

Treatment and Prevention of Recurrent Clostridium difficile Infection with Functionalized Bovine Antibody-Enriched Whey in a Hamster Primary Infection Model
por: Heidebrecht, Hans-Jürgen, et al.
Publicado: (2019)

Mutacin 1140 Lantibiotic Variants Are Efficacious Against Clostridium difficile Infection
por: Kers, Johan A., et al.
Publicado: (2018)

OG716: Designing a fit-for-purpose lantibiotic for the treatment of Clostridium difficile infections
por: Kers, Johan A., et al.
Publicado: (2018)

Susceptibility of Hamsters to Clostridium difficile Isolates of Differing Toxinotype
por: Buckley, Anthony M., et al.
Publicado: (2013)

Selectivity of the photosensitiser Tookad® for photodynamic therapy evaluated in the Syrian golden hamster cheek pouch tumour model
por: Borle, F, et al.
Publicado: (2003)

Microbiological Characterization of VNRX-5236, a Broad-Spectrum β-Lactamase Inhibitor for Rescue of the Orally Bioavailable Cephalosporin Ceftibuten as a Carbapenem-Sparing Agent against Strains of Enterobacterales Expressing Extended-Spectrum β-Lactamases and Serine Carbapenemases
por: Chatwin, Cassandra L., et al.
Publicado: (2021)

Omadacycline Gut Microbiome Exposure Does Not Induce Clostridium difficile Proliferation or Toxin Production in a Model That Simulates the Proximal, Medial, and Distal Human Colon
por: Moura, Ines B., et al.
Publicado: (2019)

Epidemic ribotypes of Clostridium (now Clostridioides) difficile are likely to be more virulent than non-epidemic ribotypes in animal models
por: Vitucci, John C., et al.
Publicado: (2020)

Infection of hamsters with the UK Clostridium difficile ribotype 027 outbreak strain R20291
por: Buckley, Anthony M., et al.
Publicado: (2011)

Uptake and localisation of mTHPC (Foscan®) and its(14)C-labelled form in normal and tumour tissues of the hamster squamous cell carcinoma model: a comparative study
por: Blant, S Andrejevic, et al.
Publicado: (2002)

In vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection
por: Abutaleb, Nader S., et al.
Publicado: (2021)

Monoclonal Antibodies Targeting Surface-Exposed Epitopes of Candida albicans Cell Wall Proteins Confer In Vivo Protection in an Infection Model
por: Palliyil, Soumya, et al.
Publicado: (2022)

In Vivo Pharmacodynamic Study of Cefiderocol, a Novel Parenteral Siderophore Cephalosporin, in Murine Thigh and Lung Infection Models
por: Nakamura, Rio, et al.
Publicado: (2019)

SMT soldering handbook
por: Strauss, Rudolf, et al.
Publicado: (1998)

MachSMT: A Machine Learning-based Algorithm Selector for SMT Solvers
por: Scott, Joseph, et al.
Publicado: (2021)

Parasite Viability as a Measure of In Vivo Drug Activity in Preclinical and Early Clinical Antimalarial Drug Assessment
por: Radohery, Georges F. R., et al.
Publicado: (2022)

Clostridium difficile Infection
por: Feuerstadt, Paul
Publicado: (2015)

Clostridium difficile infection
por: Geller, Stephen A., et al.
Publicado: (2014)

Clostridium difficile Infection
por: Magdesian, K. Gary
Publicado: (2003)

Clostridium difficile infection: review
por: Czepiel, Jacek, et al.
Publicado: (2019)

Thrombin-Derived C-Terminal Peptide Reduces Candida-Induced Inflammation and Infection In Vitro and In Vivo
por: Dahlman, Anna, et al.
Publicado: (2021)

Evaluation of the Xpert Clostridium difficile Assay for the Diagnosis of Clostridium difficile Infection
por: Shin, Saeam, et al.
Publicado: (2012)

Orthogonal polarisation spectral imaging as a new tool for the assessment of antivascular tumour treatment in vivo: a validation study
por: Pahernik, S, et al.
Publicado: (2002)

Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo
por: Theys, J, et al.
Publicado: (2006)

A Novel Ex Vivo Drug Assay for Assessing the Transmission-Blocking Activity of Compounds on Field-Isolated Plasmodium falciparum Gametocytes
por: Ouologuem, Dinkorma T., et al.
Publicado: (2022)

Limited Ability of Posaconazole To Cure both Acute and Chronic Trypanosoma cruzi Infections Revealed by Highly Sensitive In Vivo Imaging
por: Francisco, Amanda Fortes, et al.
Publicado: (2015)

No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan
por: Calvet, L, et al.
Publicado: (2004)

1344. Ridinilazole (RDZ) for Clostridium difficile Infection (CDI): Impact of Diagnostic Method on Outcomes From a Phase 2 Clinical Trial
por: Vickers, Richard, et al.
Publicado: (2018)

Clostridium difficile infections in China()
por: Jin, Ke, et al.
Publicado: (2010)

In Vivo Targeting of Escherichia coli with Vancomycin-Arginine
por: Neville, Lewis F., et al.
Publicado: (2021)

Finafloxacin Is an Effective Treatment for Inhalational Tularemia and Plague in Mouse Models of Infection
por: Barnes, Kay B., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s9b3ntnhvpecpa0i1o0fpng6uk